New Autoinjection Device Designed to Work With Betaseron(R) Now Available For Patients With MS

" Berlex, Inc. today announced the
availability of Betaject(R) 3, a new autoinjection device specifically
designed to work with Betaseron(R) (interferon beta-1b) as an optional
injection method for patients with relapsing forms of multiple sclerosis
(MS). The Betaject 3 autoinjection device is an easy-to-use, mechanical
device that automatically delivers subcutaneous injections and may help
make it easier for patients to inject their medication.
"With Betaject 3, we've simplified the process for patients by
eliminating an entire set-up step prior to each injection," said Dr. Ludger
Heeck, Vice President and General Manager of Specialized Therapeutics at
Berlex. "It complements the convenient, refrigeration free-formulation
Betaseron offers, and provides patients with an optional tool to help make
using Betaseron therapy quick and easy."
Ease of Use, Convenience and Support
The Betaject 3 autoinjection device is the latest innovation designed
to assist patients on Betaseron treatment. Eliminating a calibration step
prior to each injection, this optional injection device automatically
delivers subcutaneous injections of Betaseron at a standard preset needle
depth, allowing patients to more easily self-inject their medication than
with devices that require calibration.
Betaseron is the only available refrigeration-free MS therapy that can
be stored at room temperature for longer than 30 days(1). This unique
product attribute simplifies the injection process by eliminating waiting
time and allows patients more options for traveling with and storing their
medication in a discrete, safe manner.
Along with the availability of products designed to help simplify the
treatment process, Berlex offers personal support programs for people using
Betaseron through its MS Pathways and B.E.T.A. Nurse programs. The B.E.T.A.
Nurses assist people with MS beginning therapy with Betaseron by providing
in- person injection training. B.E.T.A. Nurses maintain ongoing
communication throughout the course of therapy to help them and their
caregivers adjust to treatment and ease some of the challenges often
associated with the disease. Research has shown that Betaseron patients who
participated in the B.E.T.A. Nurse program were more likely to maintain
their course of therapy with nearly 90 percent of people in the program
remaining on treatment after one year.
For more information about the optional Betaject 3 autoinjection
device, Betaseron or the B.E.T.A. Nurse program is available by calling MS
Pathways at 1.800.788.7467...."